The Filing Desk

Aardvark Therapeutics vs Nanoviricides

Aardvark Therapeutics AARD · Nanoviricides NNVC · Pharmaceuticals

Free cash flow was −$54 million at Aardvark Therapeutics and −$8 million at Nanoviricides. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.

Side by side

Aardvark TherapeuticsNanoviricides
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Jun 30, 2026
Revenue$0M$0M
Revenue growth——
Revenue growth a year, last 5 years——
Gross margin——
Operating margin——
Net margin——
Free cash flow−$54M−$8M
Free cash flow margin——
Return on capital—−110.8%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count391.1%33.5%
Last close$1.00$1.17
P/E at the last close——
Insider trades, last 12 monthsbought $144,630, sold $394,930—
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aardvark TherapeuticsNanoviricides
Operating margin
Percent of revenue
Aardvark TherapeuticsNanoviricides
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aardvark TherapeuticsNanoviricides

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aardvark Therapeutics and Nanoviricides pages.